Edaravone is a neuroprotective operator that is primarily accessible in the global market under the trademark ‘Radicava’ and ‘Radicut’. Since its coming in the late 1980s, edaravone is picking up ubiquity among patients recuperating from stroke and the individuals who are experiencing amyotrophic lateral sclerosis (ALS). Edaravone set foot in the US market in 2017 after the endorsement of FDA for its utilization in the treatment of ALS.
Inaccessibility of an endorsed elective medication for treating amyotrophic lateral sclerosis (ALS), aside from riluzole. The constant innovative work in the medication sector is relied upon to offer rewarding chances to the market. Every year the patients are growing in amyotrophic lateral sclerosis (ALS) which will increase the number in already diagnosed patients globally.
The global Edaravone market is segregated on the basis of Product as Injection and Oral. Based on End User the global Edaravone market is segmented in Hospital, Clinic, and Others.
The global Edaravone market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Edaravone market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Sun Pharmaceutical Industries Ltd., Unichem Laboratories Ltd, UCB India Ltd, Piramal Healthcare, Mitsubishi Tanabe Pharma, Simcere, Taj Pharmaceuticals Ltd., and others are among the major players in the global Edaravone market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Edaravone Market has been segmented as below:
Edaravone Market, By Product
Edaravone Market, By End User
Edaravone Market, By Region
Edaravone Market, By Company
The report covers:
Report Scope:
The global Edaravone market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Edaravone market share. Major industry players with significant revenue share include Sun Pharmaceutical Industries Ltd., Unichem Laboratories Ltd, UCB India Ltd, Piramal Healthcare, Mitsubishi Tanabe Pharma, Simcere, Taj Pharmaceuticals Ltd., and others.
Reasons to Buy this Report:
Customization
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
Breakthrough Therapy Drugs Market
Cellulose Ether & Its Derivatives Market
Clinical Immunochemistry Analyzers Market
1. Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach – Segmental Market Analysis
2.5.2 Top-Down Approach – Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter’s Five Force Analysis
5. Edaravone Market, By Product
5.1 Introduction
5.2 Injection
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Oral
5.3.1 Market Overview
5.3.2 Market Size and Forecast
6. Edaravone Market, By End User
6.1 Introduction
6.2 Hospital
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Clinic
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Others
6.4.1 Market Overview
6.4.2 Market Size and Forecast
7. Edaravone Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 North America Edaravone, By Product
7.2.2 North America Edaravone, By End User
7.3 Europe
7.3.1 Europe Edaravone, By Product
7.3.2 Europe Edaravone, By End User
7.4 Asia-Pacific
7.4.1 Asia-Pacific Edaravone, By Product
7.4.2 Asia-Pacific Edaravone, By End User
7.5 Rest of the World
7.5.1 Rest of the World Edaravone, By Product
7.5.2 Rest of the World Edaravone, By End User
8. Competitive Insights
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
9. Company Profiles
9.1 Sun Pharmaceutical Industries Ltd.
9.1.1 Company Overview
9.1.2 Product/Service Landscape
9.1.3 Financial Overview
9.1.4 Recent Developments
9.2 Unichem Laboratories Ltd
9.2.1 Company Overview
9.2.2 Product/Service Landscape
9.2.3 Financial Overview
9.2.4 Recent Developments
9.3 UCB India Ltd
9.3.1 Company Overview
9.3.2 Product/Service Landscape
9.3.3 Financial Overview
9.3.4 Recent Developments
9.4 Piramal Healthcare
9.4.1 Company Overview
9.4.2 Product/Service Landscape
9.4.3 Financial Overview
9.4.4 Recent Developments
9.5 Mitsubishi Tanabe Pharma
9.5.1 Company Overview
9.5.2 Product/Service Landscape
9.5.3 Financial Overview
9.5.4 Recent Developments
9.6 Simcere
9.6.1 Company Overview
9.6.2 Product/Service Landscape
9.6.3 Financial Overview
9.6.4 Recent Developments
9.7 Taj Pharmaceuticals Ltd.
9.7.1 Company Overview
9.7.2 Product/Service Landscape
9.7.3 Financial Overview
9.7.4 Recent Developments
The Edaravone Market has been segmented as below:
Edaravone Market, By Product
Edaravone Market, By End User
Edaravone Market, By Region
Edaravone Market, By Company
SUBSCRIBE TO OUR NEWSLETTERS
